| Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity. | |
| | |
MedLine Citation:
|
PMID: 16154634 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The study was conducted to determine whether the expression of behavioral supersensitivity induced by haloperidol (HAL) administered once daily (2 mg/kg i.p.) for 14 days is associated with the alterations in activity of neuropeptide Y (NPY) system in the striatum (caudate-putamen) and nucleus accumbens. Dopamine supersensitivity was tested by measurement of locomotor activity and stereotyped behavior after administration of the dopamine D2/D3 receptor agonist quinpirole (1 mg/kg i.p.) on day 1, 3 and 7 after HAL withdrawal. Neuropeptide Y-like immunoreactivity (NPY-LI) was determined in the striatum and nucleus accumbens isolated 6 h after quinpirole injection on day 1, 3 and 7 after the end of HAL treatment. NPY mRNA was quantified in these structures on day 7 after HAL withdrawal. HAL increased spontaneous locomotor activity and prevalence of rearing, grooming and head-down sniffing. At the same time, striatal NPY-LI increased progressively from the reduced level found on day 1 of haloperidol withdrawal. NPY mRNA remained unchanged. In saline-treated rats, quinpirole enhanced locomotion, rearing, and induced intense head-down sniffing and oral activity. These behavioral effects were accompanied by a decrease in striatal NPY-LI. NPY mRNA was slightly increased. HAL treatment altered response to quinpirole, namely it increased locomotion, intensified oral activity and reduced rearing and head-down sniffing. The second and the third quinpirole injection decreased NPY-LI levels. NPY mRNA was unchanged. In the nucleus accumbens, apart from a decrease in NPY-LI on day 1 after the last haloperidol dose, the level of NPY-LI and NPY mRNA in any experimental group did not differ from the control value. The presented results suggest that the alterations in the activity of the striatal but not nucleus accumbens NPY system contribute to adaptive changes induced by long-term haloperidol treatment and may be of significance to the motor hyperactivity induced by intermittent stimulation of postsynaptic dopamine D2 receptors. |
| | |
Authors:
|
E Obuchowicz; R Krysiak; J M Wieronska; M Smialowska; Z S Herman |
Related Documents
:
|
6150084 - Differential effects of 5-hydroxytryptaminergic antagonists upon apomorphine- and lergo... 7394324 - Enhanced sensitivity to pentobarbital in haloperidol or pimozide treated mice and rats. 2931624 - [3h]spiperone binding in the rat striatum during the development of physical dependence... 3923514 - Chronic haloperidol during development attenuates dopamine autoreceptor function in str... 2381204 - Influence of colloidal carbon phagocytosis as a metabolic load on the hepatic energy me... 22750154 - Anticonvulsant effect of phytol in a pilocarpine model in mice. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2005-09-09 |
Journal Detail:
|
Title: Neuropeptides Volume: 39 ISSN: 0143-4179 ISO Abbreviation: Neuropeptides Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-10-17 Completed Date: 2006-02-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8103156 Medline TA: Neuropeptides Country: Scotland |
Other Details:
|
Languages: eng Pagination: 515-23 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Silesian University School of Medicine, Medykow 18 Street, 40-752 Katowice, Poland. eobuchowicz@slam.katowice.pl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Behavior, Animal / drug effects* Corpus Striatum / cytology, drug effects*, metabolism Dopamine Agonists / pharmacology Dopamine Antagonists / pharmacology* Haloperidol / pharmacology* In Situ Hybridization Male Motor Activity / drug effects* Neuropeptide Y / genetics, metabolism* Quinpirole / pharmacology RNA, Messenger / metabolism Rats Rats, Wistar |
| Chemical | |
Reg. No./Substance:
|
0/Dopamine Agonists; 0/Dopamine Antagonists; 0/Neuropeptide Y; 0/RNA, Messenger; 52-86-8/Haloperidol; 85760-74-3/Quinpirole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Collagen composite hydrogels for vocal fold lamina propria restoration.
Next Document: Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease).